Targeted therapy directed by tumor profile is a cornerstone in the NACT – setting where a complete pathological response and long‐term outcome is superior to the HER2‐positive or the ER‐negative and HER2‐normal tumors in comparison to the luminal breast cancers for which the response to NACT is more unclear 19. This evidence concerns the gene ERBB2 and neoplasm.